<DOC>
	<DOCNO>NCT03040635</DOCNO>
	<brief_summary>This randomize , placebo-controlled study investigate safety , tolerability , pharmacokinetics pharmacodynamics single oral dos RO7034067 healthy Japanese participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics RO7034067 Healthy Japanese Participants</brief_title>
	<detailed_description />
	<criteria>Participants Japanese origin , Japanese parent ( provisional Caucasian cohort , participant must male female Caucasians 4 Caucasian grandparent ) Healthy participant . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include ophthalmological examination , vital sign , 12lead electrocardiogram ( ECG ) , hematology , blood chemistry , serology urinalysis A body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) inclusive Male participant must agree use barrier method contraception dose completion study 4 month thereafter Female participant must either surgically sterile postmenopausal Medical history cardiovascular disease , renal disease , liver disease , digestive system disease , blood dyscrasia , immunologic disease , diseases nervous system , endocrine disease , metabolic disease , lung disease , anamnesis obstacle kidney , liver , cardiopulmonary function Participants clinically significant eye pathology Laboratory test ( hematology , biochemistry , physical examination vital sign ) value outside institutional normal range rat clinically significant abnormal screen Any clinically significant abnormality ECG screen Inherited long QT syndrome know family history arrhythmia Systolic blood pressure ( SBP ) high 140 millimeter mercury ( mmHg ) 90 mmHg , and/or diastolic blood pressure ( DBP ) high 90 mmHg 50 mmHg supine position , assess screen Positive result human immunodeficiency virus ( HIV ) antigen antibody , hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibody screen Donation loss blood 500 milliliter ( mL ) within three month prior screen History smoke 10 cigarette day . Participants quit smoke reduce daily cigarette smoke 10 le one month prior screen allow Daily consumption food drink contain large amount methylxanthine ( caffeine , theophylline , theobromine ) Present past history substance addiction , dependence abuse , abuse drug alcohol Concomitant previous participation clinical trial either within 90 day 5 halflives investigational drug , whichever longer , administration study drug study Use prescribe medication systemic exposure within one week enrolment Use concomitant drug study ( include overthecounter medication medication use dentistry ) Inability meet study requirement opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>